Insights into advanced therapies in the context of evolving funding and M&A environments
Cell & Gene Therapy Insights 2024; 10(3), 223–229
DOI: 10.18609/cgti.2024.034
Published: 26 March
Interview
Lee Brown
David McCall, Senior Editor, BioInsights, spoke to Lee Brown, Healthcare Sector Global Team Leader, Third Bridge Group, on Tuesday, February 6, 2024 to gain his insights into the fast-moving market landscape of advanced therapies. The discussion outlines key recent news and strategic moves from prominent pharma and biotech companies in the field, as well as the prospects for specific technologies such as CRISPR-based genome editing and next-generation CAR-T therapies.